ASH 2017 | Using validated next-generation techniques for monitoring MRD in multiple myeloma
Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain, urges hematologists and oncologists interested in monitoring MRD in patients with multiple myeloma to only use validated, optimised next-generation techniques that have been recommended by the International Myeloma Working Group. Either NGS by Adaptive, the commercial vendor, or next-generation flow. Bruno discusses the availability of these techniques and the factors to consider when deciding which to use.
Get great new content delivered to your inboxSign up